Skip to main content
. 2017 Jun 13;157(3):478–487. doi: 10.1177/0194599817711378

Table 6.

Reported Rates of Persistent Tympanic Membrane Perforation following Intratympanic Administration.

Study Indication Treatment Anesthetic No. Follow-up, d Persistent TM Perforation, %
Rauch et al, 201118 ISSNHL 4 × methylprednisolone 40 mg/mL of over 2 weeks Phenol 129 60 3.9
Lambert et al, 201219 Ménière’s disease 1 × 3 or 12 mg dexamethasone in poloxamer gel Phenol 30 84 3.3
Nakagawa et al, 201420 SSHL 4 × 3.8 mg/mL dexamethasone over 4-7 days Lidocaine 58 112 15.5
1 × IGF-1 10 mg/mL in gelatin hydrogel 62 0.0
Lambert et al, 201621 Ménière’s disease 1 × 12 mg dexamethasone in poloxamer gel Unknown 77 120 2.7
Topf et al, 201722 Ménière’s disease or ISSHNL ≥ 1 × dexamethasone 10 mg/mL Phenol 192 90 1.6

Abbreviations: IGF-1, insulin-like growth factor 1; ISSNHL, idiopathic sudden sensorineural hearing loss; SSHL, sudden sensorineural hearing loss; TM, tympanic membrane.